Insulin Therapy Center

We all know the benefits of the newer insulins, i.e., faster action times, less peak from the long actings, etc. But the cost, more often than we know, can lead to patients decreasing insulin doses, doing without until the next payday, or doing without it altogether, as we’ve read about. …

Guest Post by David Kliff, Editor, Diabetic Investor

The so-called “high” cost of insulin continues to get lots of attention. But as I’ve noted before, little perspective has been given to this debate and far too many facts are missing. Yes, I know facts are pesky things, but they are facts nonetheless. Allow me for a moment to provide some examples.

Evaluating if bolus calculators for insulin pumps can be accurately calibrated by speech recognition.

Woman, 67 years of age, type 2 diabetes for 22 years, class II obesity. Has recently been managing her glucose levels with weight loss, using Tresiba, Trulicity, and metformin. Recent A1C 6.5%, which she’s worked hard for and been extremely proud of. She hasn’t had numbers like she has recently had for years.

Patients who skipped initial treatment with metformin and were instead started on second-line antihyperglycemic medication more likely to need dual therapy or insulin to control T2.

Congress creates abbreviated licensure pathway for biological products similar to or interchangeable with FDA-approved products.

New insulin formulation emerges as safe alternative to long-acting insulins and inconsistent glycemic levels, but could have higher risk of cardiovascular events.

Sensor-augmented therapy can diminish hypoglycemia with the low-glucose suspend feature.

Patients with type 2 diabetes not responding to basal insulin therapy alone may see glycemic improvement with a GLP-1 receptor agonist.

A new formulation of Insulin Aspart can offer better glycemic control and may also be given after meals.